Gliclazide-d4

Gliclazide-d4 (S1702 D4) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].

Product Specifications

CAS Number

[1185039-30-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Potassium Channel

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

99.90

Solubility

10 mM in DMSO|DMSO : ≥ 100mg/mL|H2O : 0.1mg/mL (ultrasonic)

Smiles

O=S(NC(NN1CC2C(CCC2)C1)=O)(C3=C([2H])C([2H])=C(C([2H])=C3[2H])C)=O

Molecular Formula

C15H17D4N3O3S

Molecular Weight

327.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Shimoyama, T., et al., Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism, 2006. 55 (6) : p. 722-30.|[3]Lawrence, C.L., et al., Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia, 2001. 44 (8) : p. 1019-25.